MiniMed aims to develop fully automated insulin pumps comparable to self-driving cars, CEO Que Dallara announced at the Consello Spark Summit following the company's recent IPO.
MiniMed is pursuing automation in diabetes management as it enters the public markets. The company's goal is to create insulin delivery systems that require minimal user intervention, similar to autonomous vehicle technology.
CEO Dallara's statement positions MiniMed as an innovator in medical device automation. The self-driving car analogy suggests the company is working toward pumps that automatically adjust insulin delivery based on continuous glucose monitoring and predictive algorithms.
Automated insulin delivery systems, sometimes called artificial pancreas technology, represent a significant advancement in diabetes care. These devices can reduce the burden of manual glucose monitoring and insulin dosing for patients.
The company's post-IPO focus on automation reflects broader industry trends toward connected health devices and AI-driven medical technology. MiniMed joins competitors like Medtronic in advancing closed-loop insulin delivery systems.
The timeline and specific technological milestones for MiniMed's autonomous pump development remain undisclosed.
US nutrition startup Berry Street has merged with Indian health platform Healthify as demand for GLP-1 weight-loss drugs accelerates. The combined entity will be led by co-CEOs Noah Kotlove and Tushar Vashisht.
Accel-backed Keenable is launching publicly with a $26 million seed round to build a specialized web search index optimized for AI agents rather than traditional search engines.
Autonomous trucking startup Gatik secured $200 million in funding led by Qatar Investment Authority and Koch Disruptive Technologies. The round, the company's largest to date, brings total funding to approximately $500 million.